Hannah M. Linden, Stephanie M. van de Ven, Paul La Porte, Peter S Conti, Parvin F. Peddi, Joanne E. Mortimer, Christiana Brenin, David A. Buck, Amol Madan Takalkar, Julia Elizabeth McGuinness, Edgar Cheng, Amol Rao, Gary A. Ulaner, Deborah L. Lindquist, Adam Brufsky, Lanell Peterson, Jennifer M. Specht, Terence Z. Wong. "Clinical utility of [ 18 F]fluoroestradiol (FES) PET/CT to guide second-line treatment decision in patients with ER-positive HER2-negative metastatic breast cancer progressing on first-line endocrine therapy.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.1059